Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.
Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.